title: Remission of severe, intractable autoimmune haemolytic anaemia following matched unrelated donor transplantation.
abstract: Immune-mediated haemolytic anaemia presenting post allogeneic bone marrow transplantation is often alloimmune in origin due to ABO or minor red cell incompatibilities. Autoimmune haemolytic anaemia is also recognised, is frequently difficult to treat and overall prognosis is often poor, usually from associated problems. Here, we present a case report of autoimmune haemolysis presenting in an 8-year-old boy 6 months post allogeneic bone marrow transplant requiring 4 years of immunosuppressive therapy before remission of haemolysis. This case report highlights the fact that it is possible for haemolysis to resolve post transplant even after years of immunosuppressive therapy.
authors.affiliation: Yorkshire Regional Centre for Paediatric Oncology and Haematology, St James's University Hospital, Leeds, UK.
authors.forename: G
authors.initials: G
authors.lastname: Pratt
authors.forename: S E
authors.initials: SE
authors.lastname: Kinsey
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000074323:Alemtuzumab; D000744:Anemia, Hemolytic, Autoimmune / Q000188:drug therapy / Q000209:etiology*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D001803:Blood Transfusion; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D002648:Child; D003131:Combined Modality Therapy; D016371:Cranial Irradiation; D003520:Cyclophosphamide; D016572:Cyclosporine / Q000008:administration & dosage; D006086:Graft vs Host Disease / Q000517:prevention & control; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000150:complications / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D008212:Lymphocyte Depletion; D008297:Male; D011239:Prednisolone / Q000008:administration & dosage; D012074:Remission Induction; D013792:Thalidomide / Q000627:therapeutic use; D019172:Transplantation Conditioning / Q000009:adverse effects; D014184:Transplantation, Homologous / Q000009:adverse effects; D014916:Whole-Body Irradiation
chemical_list: D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D000074323:Alemtuzumab; D013792:Thalidomide; D016572:Cyclosporine; D003520:Cyclophosphamide; D011239:Prednisolone